AP1S2

Across TCGA pan-cancer cohorts, AP1S2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AP1S2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AP1S2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP1S2 expression acts as an unfavorable survival marker.

UCEC, HNSC, and PDAC are the cancer types where AP1S2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.535	0.850	.049	4	view →
HNSC	OS	Median	III,IV	0.532	0.748	.021	4	view →
PDAC	DFS	Tertile	All	0.608	0.797	.019	4	view →
CCRCC	OS	Median	III,IV	0.679	0.883	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AP1S2–UCEC (DFS)

Open the UCEC breakdown →